首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > DDS > 奈米給藥技術:主要企業、產品及2018年之前的展望
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

奈米給藥技術:主要企業、產品及2018年之前的展望

Drug Delivery Technologies: Nano-enabled Delivery Players, products & prospects to 2018

出版商 Espicom Business Intelligence
出版日期 2009年06月 商品編碼 94091
內容資訊 英文 106 Pages
價格
US $ 1040 Hard Copy
US $ 1040 PDF by E-mail (Single User License)
US $ 5200 PDF (Global License)


奈米給藥技術:主要企業、產品及2018年之前的展望 是由出版商Espicom Business Intelligence在2009年06月所出版的。 這份英文市場調查報告書包含106 Pages 價格從美金1040起跳。

簡介

2018年奈米科技市場的既有奈米科技產品(約102億美元)及第二代奈米藥物(約29億美元)加總後預計將有130億美元以上的規模。

本報告書內容包括:奈米給藥技術介紹、現在及未來的新產品開發動向及2018年之前的銷售預測、技術動向、競爭動向等。內容綱要摘記如下:

實施概要

介紹

給藥技術中的奈米科技

  • 製藥公司開發的核心奈米科技
    • 奈米工程藥物
    • 奈米級載體
  • 給藥技術在奈米科技治療上的應用現況
  • 利用奈米科技給藥技術的主要品牌
  • 未來的商業用途及機會

給藥企業策略

  • 主要企業
  • 合作及收購
    • 策略性發展及商業合作
    • 合併・收購・新事業・分公司化
    • 智慧財產

奈米科技市場

  • 2009年的現況
  • 2018年的未來動向

競爭分析

  • 有力企業
  • 企業介紹
    • Abraxis Bioscience
    • Access Pharmaceuticals
    • AlphaRx Corporation
    • ALZA Corporation
    • Aphios Corporation
    • APR Applied Pharma Research
    • BioSante Pharmaceuticals
    • Calando Pharmaceuticals
    • Camurus AB
    • Cerulean Pharma Inc
    • CytImmune Sciences Inc
    • Elan Corporation
    • Enzon Pharmaceuticals, Inc.
    • Gilead Sciences
    • Introgen Therapeutics
    • Mersana Therapeutics
    • Nano Interface Technology
    • Nano S Biotechnology GmbH
    • NanoBio Corporation
    • NanoBioMagnetics
    • Nanobiotix
    • NanoCarrier
    • Nanotechnology Victoria, Ltd
    • NanoMaterials Technology
    • Nanotherapeutics
    • Novavax
    • SkyePharma
    • Spherics
    • Starpharma

附錄

目錄

Abstract

The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.

As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry' s need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.

The potential of future applications:

  • Tissue specific delivery - targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
  • Gene and vaccine delivery - non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
  • Controlled-release devices - design of new nanoporous, bioerodible membranes;
  • Increased biocompatibility - design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
  • Improved drug bioavailability and solubility - through the engineering of drugs and reagents by nanostructuring;
  • Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.

By 2018, the market could exceed US$13 billion

By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.

By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry' s delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.

This report is part of a major new 4-volume strategic analysis

  • VOLUME I: CONTROLLED- RELEASE
  • VOLUME II: NANOTECHNOLOGY
  • VOLUME III: NUCLEIC ACID DELIVERY
  • VOLUME IV: TARGETED DELIVERY

Table of Contents

EXECUTIVE SUMMARY & INTRODUCTION

  • Overview of nanotechnology: past, present & future
  • Nanotechnology: motivators & resistors
  • Nanomedicines, formulations and product regeneration

NANOTECHNOLOGY IN DRUG DELIVERY

  • Core nanotechnology used by the pharma industry
  • Nano-engineered drugs
  • Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle structures
  • Current therapeutic applications of nanotechnology in drug delivery
  • Leading brands that utilise nanotechnology delivery
  • Future commercial applications & opportunities

STRATEGIES OF DRUG DELIVERY COMPANIES

  • Leading nanotechnology drug delivery companies
  • Strategic development & commercialisation partnerships and joint ventures
  • Mergers, acquisitions, start-ups & spin offs
  • Intellectual property

THE CURRENT & FUTURE MARKET

  • Leading approved nano-enabled product sales 2009
  • Companies developing nano-enabled product sales 2009
  • Novel nano-enabled product sales 2018
  • Global nano-enabled product sales 2018

COMPETITOR ANALYSIS

Detailed analysis of leading companies covering:

  • Proprietary delivery technology
  • Applications in the pharma industry
  • Management/technical expertise
  • Competition within the delivery technology sector
  • Products in development/approved utilising the delivery technology
  • Sales forecasts of products using the delivery technology
  • Competitor ratio analysis

Companies analysed

  • Abraxis BioScience, Inc
  • Access Pharmaceuticals, Inc
  • AlphaRx Corporation
  • ALZA Corporation
  • Aphios Corporation
  • Applied Pharma Research S.A.
  • BioSante Pharmaceuticals, Inc
  • Calando Pharmaceuticals, Inc
  • Camurus A.B.
  • Cerulean Pharma, Inc
  • CytImmune Sciences, Inc
  • Elan Corporation, Plc
  • Enzon Pharmaceuticals, Inc.
  • Gilead Sciences, Inc
  • Introgen Therapeutics
  • Mersana Therapeutics
  • Nano Interface Technology
  • Nano S Biotechnology GmbH
  • NanoBio Corporation
  • NanoBioMagnetics, Inc
  • Nanobiotix, Inc
  • NanoCarrier, Inc
  • Nanotechnology Victoria, Ltd.
  • NanoMaterials Technology
  • Nanotherapeutics, Inc
  • Novavax, Inc.
  • SkyePharma, Plc
  • Spherics Pharmaceuticals, Inc
  • Starpharma Holdings, Ltd

APPENDICIES

  • Nanotechnology approved drug sales 2008-2018
  • Nanotechnology developmental drug sales 2008-2018
  • Key nanotechnology delivery companies by 2018
Back to Top